A Randomized, Controlled Trial of  Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

In this open label, multicenter study conducted over 1-year follow-up randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m2, to receive standard therapy or rituximab with standard therapy. median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl, and proteinuria was 2.1 (0.6-5.3) g/d. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. educe levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.             : Proton Pump Inhibitors and Risk of Incident CKD & Progression to ESRD Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology General Nephrology Glomerulonephritis Source Type: research